top of page
Search

ABPA for MRCP Part 1: Key Facts

TL;DR

Allergic Bronchopulmonary Aspergillosis (ABPA) is a hypersensitivity lung disease caused by immune reaction to Aspergillus fumigatus, typically in patients with asthma or cystic fibrosis. For MRCP Part 1, focus on markedly raised IgE, eosinophilia, and central bronchiectasis on imaging. Steroids—not antifungals—are first-line therapy. Recognising these classic features helps secure easy exam marks.


Why this matters

In MRCP Part 1, questions often integrate respiratory medicine with immunology and infectious diseases. Allergic Bronchopulmonary Aspergillosis (ABPA) is a classic high-yield condition that tests your ability to differentiate allergic, infective, and structural lung pathology.

Despite being conceptually straightforward, it is frequently misidentified as uncontrolled asthma or pneumonia—costing candidates easy marks. A structured, pattern-based approach is essential. Begin your preparation with a solid foundation via the MRCP Part 1 overview.


Core sections

1. Definition & Pathophysiology

ABPA is a hypersensitivity reaction to colonisation of the airways by Aspergillus fumigatus. It is not an invasive infection.

It involves:

  • Type I hypersensitivity (IgE-mediated)

  • Type III hypersensitivity (immune complex-mediated)

This leads to:

  • Chronic airway inflammation

  • Mucus plugging

  • Bronchial wall damage → bronchiectasis

2. Who gets ABPA?

Almost always occurs in:

  • Patients with asthma

  • Patients with cystic fibrosis

👉 Exam insight: If neither is present, reconsider the diagnosis.

3. Key Diagnostic Features (High-Yield Table)

Feature

Finding

Background disease

Asthma or cystic fibrosis

Total IgE

>1000 IU/mL (very high)

Eosinophils

Elevated

Aspergillus-specific IgE/IgG

Positive

Skin prick test

Immediate hypersensitivity

Imaging

Central bronchiectasis

Sputum

Fungal hyphae may be present

👉 Core pattern: Asthma + high IgE + central bronchiectasis

4. Clinical Presentation

Typical features include:

  • Worsening asthma control

  • Recurrent wheeze and breathlessness

  • Productive cough with brown mucus plugs

  • Transient pulmonary infiltrates

  • Occasional haemoptysis

These patients are often treated repeatedly for “chest infections” before diagnosis.

5. Radiological Features

Imaging is heavily tested in MRCP. Key findings:

  • Central bronchiectasis (hallmark feature)

  • “Finger-in-glove” opacities (mucus impaction)

  • Fleeting pulmonary infiltrates

👉 Important distinction:

  • Central bronchiectasis → ABPA

  • Peripheral bronchiectasis → consider alternative causes

6. Management

The cornerstone of treatment is immunosuppression, not eradication of infection.

First-line:

  • Oral corticosteroids (e.g. prednisolone)

Adjunct therapy:

  • Itraconazole (reduces fungal burden and steroid requirement)

Monitoring:

  • Serial total IgE levels

    • Falling levels = response

    • Rising levels = relapse

7. Differential Diagnosis

Condition

Distinguishing Feature

Asthma

No raised IgE or bronchiectasis

Invasive aspergillosis

Occurs in immunocompromised patients

Chronic pulmonary aspergillosis

Cavitary lung lesions

Eosinophilic pneumonia

No fungal sensitisation

8. The 5 Most Tested Subtopics

  1. Diagnostic criteria (IgE, eosinophilia, imaging)

  2. Central vs peripheral bronchiectasis

  3. Role of corticosteroids vs antifungals

  4. Association with asthma and cystic fibrosis

  5. Use of IgE levels for monitoring

9. The 5 Classic Exam Traps

  1. Treating ABPA as bacterial pneumonia

  2. Missing markedly elevated IgE

  3. Confusing ABPA with invasive aspergillosis

  4. Ignoring bronchiectasis distribution

  5. Assuming antifungals alone are sufficient

MRCP Part 1 study setup with notes and laptop for respiratory revision including ABPA

Practical examples / mini-cases

Mini-MCQ

A 32-year-old man with long-standing asthma presents with worsening breathlessness and productive cough. He reports brownish sputum. Blood tests show eosinophilia and total IgE of 1400 IU/mL. CT chest demonstrates central bronchiectasis.

What is the most appropriate initial treatment?

A. Intravenous amphotericin BB. Oral prednisoloneC. Broad-spectrum antibioticsD. Inhaled corticosteroids onlyE. Bronchodilators alone

Correct answer: B. Oral prednisolone

Explanation: ABPA is an immune-mediated condition. Systemic corticosteroids suppress the hypersensitivity reaction and are first-line treatment. Antifungals are adjuncts, not primary therapy.


Practical study-tip checklist

Use this rapid checklist before the exam:

  • ✅ Always link ABPA with asthma or cystic fibrosis

  • ✅ Memorise IgE threshold (>1000 IU/mL)

  • ✅ Identify central bronchiectasis on imaging

  • ✅ Recognise brown mucus plugs as a clue

  • ✅ Prioritise steroids as first-line treatment

  • ✅ Use IgE trends to monitor response

  • ✅ Differentiate from invasive aspergillosis

Reinforce these concepts with active recall using Free MRCP MCQs and simulate exam conditions via Start a mock test. For deeper conceptual clarity, structured teaching is available through /lectures/.


Common pitfalls (5 bullets)

  • Misdiagnosing ABPA as uncontrolled asthma

  • Treating with repeated antibiotics without improvement

  • Overlooking eosinophilia

  • Misinterpreting imaging findings

  • Forgetting that ABPA is non-invasive


FAQs

1. What is the hallmark diagnostic feature of ABPA?

The combination of central bronchiectasis and markedly elevated IgE (>1000 IU/mL) is the most characteristic finding in MRCP questions.

2. Is ABPA an infection or an allergic condition?

It is primarily a hypersensitivity reaction to fungal colonisation, not a true invasive infection.

3. Why are corticosteroids the first-line treatment?

They suppress the immune-mediated inflammatory response responsible for lung damage, which is the core pathology in ABPA.

4. How is disease activity monitored?

Serial total IgE levels are used. A fall indicates response, while a rise suggests relapse.

5. Can ABPA occur without asthma?

It is rare. ABPA is strongly associated with asthma and cystic fibrosis, and absence of these should prompt reconsideration of the diagnosis.


Ready to start?

ABPA is a predictable, high-yield topic in MRCP Part 1. Mastering its diagnostic pattern and management principles can secure straightforward marks. Build a strong foundation with the MRCP Part 1 overview, and accelerate your revision using targeted practice and mock exams from Crack Medicine.


Sources

 
 
 

Comments

bottom of page